Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Helmerich & Payne Inc. Common Stock (HP) vs Merck & Co., Inc. (MRK) Price & Performance

Helmerich & Payne Inc. Common StockTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Helmerich & Payne Inc. Common Stock vs Merck & Co., Inc. — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.91B), while Merck & Co., Inc. trades at $150.66 (market cap $350.29B). The key difference: Merck & Co., Inc. is far larger — about 89.6× Helmerich & Payne Inc. Common Stock's market cap, and Helmerich & Payne Inc. Common Stock pays the higher dividend (2.56%). Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and Merck & Co., Inc. for 98 Days on average.

HPMRK
Market Cap
$3.91B$350.29B
Volume
800,3828,158,912
Sector
EnergyHealth
52-Week High
$47.64$156.43
52-Week Low
$23.11$82.49
Typical Hold Time
0 Days98 Days
Enterprise Value
$5.54B$397.05B
Dividend Yield
2.56%2.39%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Helmerich & Payne Inc. Common Stock

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.

The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HP
100% Buy0% Sell
Avg holding period · 0 Days
MRK
57% Buy43% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About Helmerich & Payne Inc. Common Stock

Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.

Read more on HP →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →